Innovative Molecules Expands Virology Pipeline with Novel EBV Antiviral Program
MUNICH, June 16, 2026 /PRNewswire/ — Innovative Molecules GmbH (“IM”), a clinical-stage biopharmaceutical company focused on herpesvirus-mediated diseases, today announced the advancement of its virology pipeline with the addition of a novel Epstein-Barr
